

Paolo Pronzato

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1534507/publications.pdf>

Version: 2024-02-01

177
papers

4,640
citations

147566

31
h-index

114278

63
g-index

182
all docs

182
docs citations

182
times ranked

5003
citing authors

#	ARTICLE	IF	CITATIONS
1	HER2 Status and Efficacy of Adjuvant Anthracyclines in Early Breast Cancer: A Pooled Analysis of Randomized Trials. <i>Journal of the National Cancer Institute</i> , 2008, 100, 14-20.	3.0	344
2	Effect of the Gonadotropin-Releasing Hormone Analogue Triptorelin on the Occurrence of Chemotherapy-Induced Early Menopause in Premenopausal Women With Breast Cancer. <i>JAMA - Journal of the American Medical Association</i> , 2011, 306, 269-76.	3.8	311
3	Increasing the dose intensity of chemotherapy by more frequent administration or sequential scheduling: a patient-level meta-analysis of 37â€™298 women with early breast cancer in 26 randomised trials. <i>Lancet, The</i> , 2019, 393, 1440-1452.	6.3	260
4	Ovarian Suppression With Triptorelin During Adjuvant Breast Cancer Chemotherapy and Long-term Ovarian Function, Pregnancies, and Disease-Free Survival. <i>JAMA - Journal of the American Medical Association</i> , 2015, 314, 2632.	3.8	180
5	Ovarian suppression using luteinizing hormone-releasing hormone agonists during chemotherapy to preserve ovarian function and fertility of breast cancer patients: a meta-analysis of randomized studies. <i>Annals of Oncology</i> , 2015, 26, 2408-2419.	0.6	178
6	Gonadotropin-releasing hormone analogues for the prevention of chemotherapy-induced premature ovarian failure in cancer women: Systematic review and meta-analysis of randomized trials. <i>Cancer Treatment Reviews</i> , 2014, 40, 675-683.	3.4	169
7	Management of anaemia and iron deficiency in patients with cancer: ESMO Clinical Practice Guidelines. <i>Annals of Oncology</i> , 2018, 29, iv96-iv110.	0.6	158
8	Multicenter randomized controlled clinical trial to evaluate cardioprotection of dexrazoxane versus no cardioprotection in women receiving epirubicin chemotherapy for advanced breast cancer.. <i>Journal of Clinical Oncology</i> , 1996, 14, 3112-3120.	0.8	146
9	Dose-Dense Adjuvant Chemotherapy in Early Breast Cancer Patients: Results From a Randomized Trial. <i>Journal of the National Cancer Institute</i> , 2005, 97, 1724-1733.	3.0	146
10	Nine weeks versus 1 year adjuvant trastuzumab in combination with chemotherapy: final results of the phase III randomized Short-HER study. <i>Annals of Oncology</i> , 2018, 29, 2328-2333.	0.6	124
11	Adjuvant tamoxifen in primary breast cancer: Influence on plasma lipids and antithrombin III levels. <i>Breast Cancer Research and Treatment</i> , 1988, 12, 307-310.	1.1	123
12	What do advanced cancer patients know of their disease?. <i>Supportive Care in Cancer</i> , 1994, 2, 242-244.	1.0	119
13	Hyaluronidase as an antidote to extravasation of Vinca alkaloids: Clinical results. <i>Journal of Cancer Research and Clinical Oncology</i> , 1994, 120, 505-506.	1.2	118
14	Multigene assays and molecular markers in breast cancer: systematic review of health economic analyses. <i>Breast Cancer Research and Treatment</i> , 2013, 139, 621-637.	1.1	87
15	The five â€™sâ€™ for bone pain due to the administration of granulocyte-colony stimulating factors (G-CSFs). <i>Critical Reviews in Oncology/Hematology</i> , 2014, 89, 112-128.	2.0	87
16	Intramuscular depot medroxyprogesterone versus oral megestrol for the control of postmenopausal hot flashes in breast cancer patients: a randomized study. <i>Annals of Oncology</i> , 2002, 13, 883-888.	0.6	82
17	Gene expression profiling in breast cancer: A clinical perspective. <i>Breast</i> , 2013, 22, 109-120.	0.9	73
18	Impact of Third-Generation Drugs on the Activity of First-Line Chemotherapy in Advanced Non-Small Cell Lung Cancer: A Meta-Analytical Approach. <i>Oncologist</i> , 2009, 14, 497-510.	1.9	64

#	ARTICLE	IF	CITATIONS
19	Conventional versus cytokinetic polychemotherapy with estrogenic recruitment in metastatic breast cancer: results of a randomized cooperative trial.. Journal of Clinical Oncology, 1987, 5, 339-347.	0.8	63
20	Impact of Administration-Related Factors on Outcome of Adjuvant Chemotherapy for Primary Breast Cancer. American Journal of Clinical Oncology: Cancer Clinical Trials, 1989, 12, 481-485.	0.6	54
21	Multicentric, Randomized Phase III Trial of Two Different Adjuvant Chemotherapy Regimens plus Three Versus Twelve Months of Trastuzumab in Patients with HER2-Positive Breast Cancer (Short-HER Trial); Tj ETQq1 1 01784314 rgt /Over	1.7	143
22	Breast cancer in elderly women: a different reality? Results from the NORA study. Annals of Oncology, 2007, 18, 991-996.	0.6	51
23	Chemotherapy with estrogenic recruitment and surgery in locally advanced breast cancer: Clinical and cytokinetic results. International Journal of Cancer, 1987, 40, 490-494.	2.3	48
24	Second Line Chemotherapy with Ifosfamide as Outpatient Treatment for Advanced Bladder Cancer. American Journal of Clinical Oncology: Cancer Clinical Trials, 1997, 20, 519-521.	0.6	46
25	Efficacy of recombinant alpha-interferon 2a and 13-cis-retinoic acid in the treatment of squamous cell carcinoma. Annals of Oncology, 1994, 5, 463-465.	0.6	42
26	Locally advanced non-metastatic breast cancer: Analysis of prognostic factors in 125 patients homogeneously treated with a combined modality approach. European Journal of Cancer, 1995, 31, 1428-1433.	1.3	41
27	Accelerated-Intensified Cyclophosphamide, Epirubicin, and Fluorouracil (CEF) Compared With Standard CEF in Metastatic Breast Cancer Patients: Results of a Multicenter, Randomized Phase III Study of the Italian Gruppo Oncologico Nord-Ouestâ€Mammella Inter Gruppo Group. Journal of Clinical Oncology, 2001, 19, 2213-2221.	0.8	41
28	Characteristics of disease activity able to identify risk categories and probability to respond to first-line endocrine therapy (ET) in HR+ve/HER2-ve metastatic breast cancer (MBC) patients (pts): Dream or reality? Evaluation of a composite risk score in a subgroup population of the GIM 13-AMBRA study.. Journal of Clinical Oncology, 2017, 35, 1049-1049.	0.8	39
29	Combined cisplatin, doxorubicin, and mitomycin for the treatment of advanced pleural mesothelioma. , 1997, 79, 1897-1902.		38
30	Assessing the Impact of the COVID-19 Outbreak on the Attitudes and Practice of Italian Oncologists Toward Breast Cancer Care and Related Research Activities. JCO Oncology Practice, 2020, 16, e1304-e1314.	1.4	38
31	Medical approaches to preservation of fertility in female cancer patients. Expert Opinion on Pharmacotherapy, 2011, 12, 387-396.	0.9	35
32	Relationship of variations in tumor cell kinetics induced by primary chemotherapy to tumor regression and prognosis in locally advanced breast cancer. Breast Cancer Research and Treatment, 1994, 32, 311-318.	1.1	33
33	Targeting the VEGF pathway: Antiangiogenic strategies in the treatment of non-small cell lung cancer. Critical Reviews in Oncology/Hematology, 2008, 68, 183-196.	2.0	33
34	Pathological and molecular characteristics distinguishing contralateral metastatic from new primary breast cancer. Annals of Oncology, 2010, 21, 1237-1242.	0.6	29
35	HER2-positive metastatic breast cancer: A changing scenario. Critical Reviews in Oncology/Hematology, 2015, 95, 78-87.	2.0	29
36	Randomized cooperative study of perioperative chemotherapy in breast cancer.. Journal of Clinical Oncology, 1995, 13, 2712-2721.	0.8	28

#	ARTICLE	IF	CITATIONS
37	Epoetin Alfa Improves Anemia and Anemia-Related, Patient-Reported Outcomes in Patients with Breast Cancer Receiving Myelotoxic Chemotherapy: Results of a European, Multicenter, Randomized, Controlled Trial. <i>Oncologist</i> , 2010, 15, 935-943.	1.9	27
38	Biological Characteristics and Medical Treatment of Breast Cancer in Young Women—A Featured Population: Results from the NORA Study. <i>International Journal of Breast Cancer</i> , 2011, 2011, 1-6.	0.6	27
39	Concurrent vs Sequential Adjuvant Chemotherapy and Hormone Therapy in Breast Cancer: A Multicenter Randomized Phase III Trial. <i>Journal of the National Cancer Institute</i> , 2011, 103, 1529-1539.	3.0	27
40	Phase II study of lonidamine in metastatic breast cancer. <i>British Journal of Cancer</i> , 1989, 59, 251-253.	2.9	25
41	Novel 2-[(benzylamino)methyl]pyrrolidine-3,4-diol derivatives as α -mannosidase inhibitors and with antitumor activities against hematological and solid malignancies. <i>Bioorganic and Medicinal Chemistry</i> , 2010, 18, 3320-3334.	1.4	24
42	Pemetrexed for the treatment of non-small cell lung cancer. <i>Expert Opinion on Pharmacotherapy</i> , 2013, 14, 1545-1558.	0.9	24
43	First line chemotherapy of metastatic breast cancer. <i>Annals of Oncology</i> , 2006, 17, v165-v168.	0.6	23
44	An Italian cost-effectiveness analysis of paclitaxel albumin (nab-paclitaxel) versus conventional paclitaxel for metastatic breast cancer patients: the COSTANza study. <i>ClinicoEconomics and Outcomes Research</i> , 2013, 5, 125.	0.7	23
45	Role of immunotherapy in the treatment of advanced non-small-cell lung cancer. <i>Future Oncology</i> , 2014, 10, 79-90.	1.1	23
46	The treatment of melanoma brain metastases before the advent of targeted therapies. <i>Melanoma Research</i> , 2014, 24, 61-67.	0.6	22
47	New Therapeutic Options for Chemotherapy-Resistant Metastatic Breast Cancer. <i>Drugs</i> , 2008, 68, 139-146.	4.9	21
48	A prospective observational study to evaluate G-CSF usage in patients with solid tumors receiving myelosuppressive chemotherapy in Italian clinical oncology practice. <i>Medical Oncology</i> , 2014, 31, 797.	1.2	21
49	Tamoxifen and interferon-beta for the treatment of metastatic breast cancer. <i>Breast Cancer Research and Treatment</i> , 1996, 39, 235-238.	1.1	20
50	Free drugs in clinical trials and their potential cost saving impact on the National Health Service: A retrospective cost analysis in Italy. <i>Lung Cancer</i> , 2013, 81, 236-240.	0.9	20
51	Survival of Patients with Relapsing Breast Cancer: Analysis of 302 Patients. <i>Oncology</i> , 1986, 43, 278-282.	0.9	19
52	Standard of Care for Cancer-Related Anemia: Improving Hemoglobin Levels and Quality of Life. <i>Oncology</i> , 2005, 68, 22-32.	0.9	19
53	Ipilimumab (MDX-010) in the treatment of non-small cell lung cancer. <i>Expert Opinion on Biological Therapy</i> , 2012, 12, 939-948.	1.4	19
54	Trastuzumab as first-line therapy in HER2-positive metastatic breast cancer patients. <i>Expert Review of Anticancer Therapy</i> , 2012, 12, 1391-1405.	1.1	19

#	ARTICLE	IF	CITATIONS
55	Safety and efficacy outcomes with erythropoiesis-stimulating agents in patients with breast cancer: a meta-analysis. <i>Annals of Oncology</i> , 2015, 26, 688-695.	0.6	19
56	Is salvage chemotherapy for metastatic breast cancer always effective and well tolerated? A phase II randomized trial of vinorelbine versus 5-fluorouracil plus leucovorin versus combination of mitoxantrone, 5-fluorouracil plus leucovorin. <i>Breast Cancer Research and Treatment</i> , 2000, 60, 195-200.	1.1	18
57	Timing of adjuvant chemotherapy and tamoxifen in women with breast cancer: findings from two consecutive trials of Gruppo Oncologico Nord-Ovestâ€™Mammella Intergruppo (GONO-MIC) Group. <i>Annals of Oncology</i> , 2008, 19, 299-307.	0.6	18
58	Carboplatin and vinorelbine in advanced non-small-cell lung cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 1996, 37, 610-612.	1.1	17
59	Sublethal Doses of an Anti-erbB2 Antibody Leads to Death by Apoptosis in Cardiomyocytes Sensitized by Low Prosenescent Doses of Epirubicin: The Protective Role of Dexrazoxane. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2010, 332, 87-96.	1.3	17
60	Pegfilgrastim administration after 24 or 72 or 96Âh to allow dose-dense anthracycline- and taxane-based chemotherapy in breast cancer patients: a single-center experience within the GIM2 randomized phase III trial. <i>Supportive Care in Cancer</i> , 2016, 24, 1285-1294.	1.0	17
61	Assessment of RT-PCR detection of human mammaglobin for the diagnosis of breast cancer derived pleural effusions. <i>Journal of Clinical Oncology</i> , 2008, 26, 1112-1112.	0.8	17
62	Pegfilgrastim for the prevention of chemotherapy-induced febrile neutropenia in patients with solid tumors. <i>Expert Opinion on Biological Therapy</i> , 2015, 15, 1799-1817.	1.4	16
63	Concurrent versus sequential adjuvant chemo-endocrine therapy in hormone-receptor positive early stage breast cancer patients: a systematic review and meta-analysis. <i>Breast</i> , 2017, 33, 104-108.	0.9	16
64	Cancer-related anaemia management in the 21st century. <i>Cancer Treatment Reviews</i> , 2006, 32, S1-S3.	3.4	15
65	Luteinising hormone releasing hormone agonists (LH-RHa) in premenopausal early breast cancer patients: Current role and future perspectives. <i>Cancer Treatment Reviews</i> , 2011, 37, 208-211.	3.4	15
66	Clinical activity and cardiac tolerability of non-pegylated liposomal doxorubicin in breast cancer: a synthetic review. <i>Tumori</i> , 2011, 97, 690-2.	0.6	15
67	Long-Term Outcomes With Pharmacological Ovarian Suppression During Chemotherapy in Premenopausal Early Breast Cancer Patients. <i>Journal of the National Cancer Institute</i> , 2022, 114, 400-408.	3.0	15
68	Chemotherapy with or without estrogenic recruitment in metastatic breast cancer. A randomized trial of the Gruppo Oncologico Nord Ovest (GONO). <i>Annals of Oncology</i> , 1996, 7, 487-490.	0.6	14
69	Topotecan and ifosfamide as salvage treatment in advanced ovarian cancer. <i>Gynecologic Oncology</i> , 2004, 93, 474-478.	0.6	14
70	Adjuvant systemic treatment of early breast cancer: the NORA study. <i>Annals of Oncology</i> , 2006, 17, 1386-1392.	0.6	14
71	Adjuvant endocrine therapy for perimenopausal women with early breast cancer. <i>Breast</i> , 2009, 18, 2-7.	0.9	14
72	New Understanding of the Role of Anthracyclines in Early-Stage Breast Cancer: Patient Selection Considerations. <i>Clinical Breast Cancer</i> , 2008, 8, S179-S183.	1.1	13

#	ARTICLE	IF	CITATIONS
73	Estrone Sulphate, FSH, and Testosterone Levels in Two Male Breast Cancer Patients Treated with Aromatase Inhibitors. <i>Oncologist</i> , 2010, 15, 1270-1272.	1.9	13
74	Anti-cancer activity of 5-O-alkyl 1,4-imino-1,4-dideoxyribitols. <i>Bioorganic and Medicinal Chemistry</i> , 2011, 19, 7720-7727.	1.4	13
75	Megestrol acetate: Phase II study of a single daily administration in advanced breast cancer. <i>Breast Cancer Research and Treatment</i> , 1990, 17, 51-54.	1.1	12
76	CMV infection and pneumonia in hematological malignancies. <i>Journal of Infection and Chemotherapy</i> , 2003, 9, 265-267.	0.8	12
77	Epirubicin and Gemcitabine as First-Line Treatment in Malignant Pleural Mesothelioma. <i>Tumori</i> , 2005, 91, 15-18.	0.6	12
78	5-Fluorouracil, epirubicin and cyclophosphamide versus epirubicin and paclitaxel in node-positive early breast cancer: a phase-III randomized GONO-MIG5 trial. <i>Breast Cancer Research and Treatment</i> , 2016, 155, 117-126.	1.1	12
79	Stevens-Johnson syndrome after treatment with bendamustine. <i>Leukemia Research</i> , 2012, 36, e153-e154.	0.4	11
80	New insights on the role of luteinizing hormone releasing hormone agonists in premenopausal early breast cancer patients. <i>Cancer Treatment Reviews</i> , 2016, 42, 18-23.	3.4	11
81	In vivo manipulation of human breast cancer growth by estrogens and growth hormone: Kinetic and clinical results. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 1990, 37, 1103-1108.	1.2	10
82	Phase II study of vinorelbine and ifosfamide in anthracycline resistant metastatic breast cancer. <i>Breast Cancer Research and Treatment</i> , 1997, 42, 183-186.	1.1	10
83	High-dose intensity cyclophosphamide, epidoxorubicin, vincristine and prednisone by shortened intervals and granulocyte colony-stimulating factor in non-Hodgkin's lymphoma: a phase II study. <i>British Journal of Cancer</i> , 1998, 78, 777-780.	2.9	10
84	Epoetin beta therapy in patients with solid tumours. <i>Critical Reviews in Oncology/Hematology</i> , 2006, 58, 46-52.	2.0	10
85	Trastuzumab emtansine in the treatment of <i>HER-2</i>-positive metastatic breast cancer patients. <i>Future Oncology</i> , 2013, 9, 955-957.	1.1	10
86	Second-line single-agent chemotherapy in human epidermal growth factor receptor 2-negative metastatic breast cancer: A systematic review. <i>Cancer Treatment Reviews</i> , 2016, 43, 36-49.	3.4	10
87	Assessment of RT-PCR Detection of Human Mammaglobin for the Diagnosis of Breast Cancer Derived Pleural Effusions. <i>Diagnostic Molecular Pathology</i> , 2008, 17, 28-33.	2.1	10
88	Oral Chemotherapy with Idarubicin plus Cyclophosphamide in Advanced Breast Cancer. <i>Chemotherapy</i> , 1991, 37, 449-453.	0.8	9
89	Mitoxantrone and mitomycin C as second-line treatment for advanced breast cancer. <i>Annals of Oncology</i> , 1992, 3, 165-166.	0.6	9
90	Second-Line Hormonotherapy for Breast Cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 1993, 16, 522-525.	0.6	9

#	ARTICLE	IF	CITATIONS
91	Thymidine Labeling Index Analysis in Early Breast Cancer Patients Randomized to Receive Perioperative Chemotherapy. <i>Oncology</i> , 2001, 60, 88-93.	0.9	9
92	Dose and outcome: The hurdle of neutropenia (Review). <i>Oncology Reports</i> , 2006, 16, 233.	1.2	9
93	Adjuvant treatment of early breast cancer: do the St Gallen recommendations influence clinical practice? Results from the NORA study. <i>Annals of Oncology</i> , 2007, 18, 1976-1980.	0.6	9
94	The administration of gefitinib in patients with advanced non-small-cell lung cancer after the failure of erlotinib. <i>Cancer Chemotherapy and Pharmacology</i> , 2012, 69, 1407-1412.	1.1	9
95	A Phase II Study with Danazol in Metastatic Breast Cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 1987, 10, 407-409.	0.6	8
96	A feasibility study of accelerated polychemotherapy with cisplatin, epidoxorubicin and cyclophosphamide (PEC) in advanced ovarian cancer. <i>British Journal of Cancer</i> , 1996, 73, 1425-1427.	2.9	8
97	Anthacyclines in non-small cell lung cancer. <i>Lung Cancer</i> , 2001, 34, 57-59.	0.9	8
98	Patterns of Relapse and Modalities of Treatment of Breast Cancer: The "IRIS"™ Project, a Multicenter Observational Study. <i>Oncology</i> , 2004, 66, 260-268.	0.9	8
99	Attitude of Italian medical oncologists toward palliative care for patients with advanced cancer: results of the SIO project. <i>Supportive Care in Cancer</i> , 2011, 19, 381-389.	1.0	8
100	Role of fulvestrant in the treatment of postmenopausal metastatic breast cancer patients. <i>Expert Review of Clinical Pharmacology</i> , 2016, 9, 1153-1161.	1.3	8
101	Long-term outcome results of the phase III PROMISE-GIM6 study evaluating the role of LHRH analog (LHRHa) during chemotherapy (CT) as a strategy to reduce ovarian failure in early breast cancer (BC) patients.. <i>Journal of Clinical Oncology</i> , 2014, 32, 105-105.	0.8	8
102	Sequential Administration of Cyclophosphamide, Methotrexate, 5-Fluorouracil, and Folinic Acid as Salvage Treatment in Metastatic Breast Cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 1987, 10, 404-406.	0.6	7
103	Phase II Trial of Oral Idarubicin in Advanced Non-Small Cell Lung Cancer (NSCLC). <i>Cancer Investigation</i> , 1988, 6, 409-411.	0.6	7
104	Lonidamine plus epirubicin and cyclophosphamide in advanced breast cancer. A phase II study. <i>European Journal of Cancer</i> , 1996, 32, 176-177.	1.3	7
105	A Dose Finding Study for the Combination of Epidoxorubicin and Vinorelbine, Delivered Every Two Weeks with G-CSF Support, in Advanced Breast Cancer. <i>Journal of Chemotherapy</i> , 1998, 10, 326-330.	0.7	7
106	A Phase II Study of a Three-Drug Combination (Cisplatin, Ifosfamide and Vinorelbine) plus Granulocyte-Colony Stimulating Factor in Advanced Non Small Cell Lung Cancer. <i>Journal of Chemotherapy</i> , 1999, 11, 306-309.	0.7	7
107	Bone metastases from head and neck malignancies: Prognostic factors and skeletal-related events. <i>PLoS ONE</i> , 2019, 14, e0213934.	1.1	7
108	Cisplatin and 5-fluorouracil in refractory breast cancer patients: A phase II study. <i>Breast Cancer Research and Treatment</i> , 1988, 11, 269-271.	1.1	6

#	ARTICLE	IF	CITATIONS
109	Impact of Irradiation of Residual Breast on Adjuvant Chemotherapy Dose Intensity. American Journal of Clinical Oncology: Cancer Clinical Trials, 1993, 16, 58-60.	0.6	6
110	Carboplatin and Etoposide as Outpatient Treatment of Advanced Non-Small-Cell Lung Cancer. Chemotherapy, 1994, 40, 144-148.	0.8	6
111	A Randomized Trial of Chemotherapy with or without Estrogenic Recruitment in Locally Advanced Breast Cancer. Tumori, 1997, 83, 829-833.	0.6	6
112	A Dose Finding Study of Carboplatin and Gemcitabine in Advanced Non-Small Cell Lung Cancer. Journal of Chemotherapy, 2002, 14, 296-300.	0.7	6
113	Cyclophosphamide, epirubicin, and 5-fluorouracil versus epirubicin plus paclitaxel in node-positive early breast cancer patients: A randomized, phase III study of Gruppo Oncologico Nord Ovest-Mammella Intergruppo Group. Journal of Clinical Oncology, 2008, 26, 516-516.	0.8	6
114	Multimodality Treatment of Locally Advanced Breast Cancer. Oncology, 1987, 44, 137-141.	0.9	5
115	Role of everolimus in the treatment of metastatic HER2-negative/HR-positive breast cancer. Future Oncology, 2017, 13, 1371-1384.	1.1	5
116	The Role of Lonidamine in the Treatment of Breast Cancer Patients. Annals of the New York Academy of Sciences, 1993, 698, 349-356.	1.8	4
117	Carboplatin, Methotrexate, and Vinblastine in Outpatients with Advanced Transitional Cell Carcinoma of the Bladder. American Journal of Clinical Oncology: Cancer Clinical Trials, 1995, 18, 223-225.	0.6	4
118	Synthesis of new oxathiazinane dioxides and their in vitro cancer cell growth inhibitory activity. Bioorganic and Medicinal Chemistry Letters, 2010, 20, 5353-5356.	1.0	4
119	Hormonal therapy followed by chemotherapy or the reverse sequence as first-line treatment of hormone-responsive, human epidermal growth factor receptor-2 negative metastatic breast cancer patients: results of an observational study. Oncotarget, 2017, 8, 44800-44810.	0.8	4
120	Continuous Venous Infusion of Vinblastine in Metastatic Breast Cancer. Chemotherapy, 1991, 37, 146-149.	0.8	3
121	Stimulation of Human Breast Cancer in Vivo.. Annals of the New York Academy of Sciences, 1993, 698, 418-422.	1.8	3
122	Re: Acute Myeloid Leukemia or Myelodysplastic Syndrome Following Use of Granulocyte Colony-Stimulating Factors During Breast Cancer Adjuvant Chemotherapy. Journal of the National Cancer Institute, 2007, 99, 1050-1051.	3.0	3
123	Letrozole withdrawal response in locally advanced breast cancer. Annals of Oncology, 2011, 22, 1927-1928.	0.6	3
124	Treatment options in HR+/HER2- advanced breast cancer patients pretreated with nonsteroidal aromatase inhibitors: what does current evidence tell us?. Future Oncology, 2015, 11, 975-981.	1.1	3
125	Safety and efficacy of immune checkpoint inhibitors in non-small-cell lung cancer: focus on challenging populations. Immunotherapy, 2021, 13, 509-525.	1.0	3
126	P1-10-05: Is the 21-Gene Breast Cancer Test (Oncotype DX®) Cost-Effective?. , 2011, , .		3

#	ARTICLE	IF	CITATIONS
127	Gemcitabine (GEM) as salvage therapy in patients (pts) with advanced colorectal cancer (CRC) refractory to 5-fluorouracil (FU), irinotecan (IRI) and oxaliplatin (OXA). <i>Journal of Clinical Oncology</i> , 2004, 22, 3577-3577.	0.8	3
128	Docetaxel (D) versus docetaxel/gemcitabine (D&G) in the treatment of older patients with advanced non-small cell lung cancer (NSCLC): An Alpe Adria Thoracic Oncology Multidisciplinary Group randomized phase II trial (ATOM 017).. <i>Journal of Clinical Oncology</i> , 2010, 28, e18028-e18028.	0.8	3
129	A Randomized Trial on Tamoxifen Continuation during Second-Line Hormone Therapy in Breast Cancer. <i>Annals of the New York Academy of Sciences</i> , 1993, 698, 357-361.	1.8	2
130	Mitoxantrone and 5-fluorouracil modulated by the pure (6S) stereoisomer of leucovorin as second-line chemotherapy for advanced breast cancer. <i>European Journal of Cancer</i> , 1994, 30, 1593-1594.	1.3	2
131	High-dose-intensity combination chemotherapy for advanced sarcomas: a pilot study. <i>Cancer Chemotherapy and Pharmacology</i> , 1998, 41, 513-516.	1.1	2
132	A Three-Drug Regimen (Gemcitabine, Ifosfamide and Cisplatin) for Advanced Non-Small-Cell Lung Cancer. <i>Journal of Chemotherapy</i> , 2001, 13, 202-205.	0.7	2
133	B2-07: Impact of 3rd generation drugs on the activity of first-line chemotherapy in advanced non-small cell lung cancer (NSCLC): a meta-analytical approach. <i>Journal of Thoracic Oncology</i> , 2007, 2, S339.	0.5	2
134	Use in current clinical practice of 70-gene signature in early breast cancer. <i>International Journal of Cancer</i> , 2010, 127, 2736-2737.	2.3	2
135	Triple-negative (TNBC) metastatic breast cancer (MBC) patients (pts): Is chemotherapy (CHT) choice influenced by adjuvant (adj) treatments? Results from the GIM-13 AMBRA study.. <i>Journal of Clinical Oncology</i> , 2019, 37, e12549-e12549.	0.8	2
136	Cytokinetic studies and treatment results of estrogens followed by chemotherapy in locally advanced (LABC) and metastatic (MBC) human breast cancer. <i>European Journal of Cancer & Clinical Oncology</i> , 1986, 22, 728.	0.9	1
137	Vinorelbine and paclitaxel in advanced breast cancer. <i>European Journal of Cancer</i> , 1999, 35, S321.	1.3	1
138	What is the optimal strategy for postoperative treatment with aromatase inhibitors in the adjuvant setting?. <i>Best Practice and Research in Clinical Endocrinology and Metabolism</i> , 2006, 20, S31-S45.	2.2	1
139	Trastuzumab before breast surgery: is concurrent administration with anthracycline-containing chemotherapy necessary?. <i>Annals of Oncology</i> , 2010, 21, 1376-1377.	0.6	1
140	HM35 Role of temporary ovarian suppression obtained with GnRH analogue in reducing premature ovarian failure induced by chemotherapy in premenopausal cancer patients: a meta-analysis of randomized studies. <i>Breast</i> , 2012, 21, S13.	0.9	1
141	1957 Ovarian suppression with luteinizing hormone-releasing hormone agonists during chemotherapy as a strategy to preserve ovarian function and fertility in breast cancer patients: A systematic review and meta-analysis of randomized studies. <i>European Journal of Cancer</i> , 2015, 51, S318-S319.	1.3	1
142	Single-nucleotide polymorphisms (SNPs) of CYP19A1 and plasma levels of estrone sulfate (ES) in postmenopausal women with breast cancer (BC) during letrozole (L) treatment.. <i>Journal of Clinical Oncology</i> , 2010, 28, 2606-2606.	0.8	1
143	The triple-negative (TN) treatment approach in Italy, from NEMESI, a retrospective observational study on early breast cancer (EBC) management.. <i>Journal of Clinical Oncology</i> , 2010, 28, e11037-e11037.	0.8	1
144	Validation of time to treatment change (TTC) as a surrogate end-point of progression free survival (PFS) for observational trials in metastatic breast cancer patients (MBC): The GIM-13 AMBRA study.. <i>Journal of Clinical Oncology</i> , 2018, 36, e13081-e13081.	0.8	1

#	ARTICLE	IF	CITATIONS
145	Choice of treatment and adherence to international ESO-ESMO (ABC) guidelines in HR+/HER2-ve metastatic breast cancer (MBC) patients (pts).. Journal of Clinical Oncology, 2017, 35, 1057-1057.	0.8	1
146	The role of taxanes in HR+ve/HER2-ve metastatic breast cancer (MBC) patients (pts) from adjuvant to metastatic setting in the clinical practice: Results from GIM13-AMBRA study.. Journal of Clinical Oncology, 2017, 35, 1055-1055.	0.8	1
147	Failure of mitomycin-vindesine combination chemotherapy as salvage treatment for metastatic breast cancer. Journal of Cancer Research and Clinical Oncology, 1985, 110, 77-78.	1.2	0
148	A Phase II Trial of Carboplatin, Methotrexate and Fluorouracil in Fluorouracil-Pretreated Colorectal Cancer. Journal of Chemotherapy, 1998, 10, 254-257.	0.7	0
149	P-584 Single agent gemcitabine (GEM) in performance status (PS) 2-3 patients (pts) with advanced non-small cell lung cancer (NSCLC): Effect on disease-related symptoms in a multicenter phase II trial. Lung Cancer, 2005, 49, S272.	0.9	0
150	6612 POSTER Disease stabilization (SD) as a surrogate end-point in advanced non-small-cell lung cancer (NSCLC) patients treated with erlotinib (E) or gefitinib (G). European Journal of Cancer, Supplement, 2007, 5, 392.	2.2	0
151	Response:Re: HER2 Status and Efficacy of Adjuvant Anthracyclines in Early Breast Cancer: A Pooled Analysis of Randomized Trials. Journal of the National Cancer Institute, 2008, 100, 680-681.	3.0	0
152	The anthracyclines and the clinical practice: do all breast cancer patients benefit? Results from the NORA study. Annals of Oncology, 2008, 19, 1811-1812.	0.6	0
153	102 How the 70-gene tumour expression profile -MammaPrint- can assist in St Gallen 2009 treatment recommendations in 12 Italian hospitals. European Journal of Cancer, Supplement, 2010, 8, 88.	2.2	0
154	The relevance of stable disease (SD) as a surrogate end-point in advanced non-small cell lung cancer (NSCLC) patients treated with erlotinib (E) as the second/third line. Lung Cancer, 2012, 77, S30-S31.	0.9	0
155	OR30 Prospective study of fertility preservation strategies in young early breast cancer patients: the PREFER (pregnancy and fertility) trial. Breast, 2014, 23, S12.	0.9	0
156	1517 Emergency department as place of end-of-life care and death in cancer patients. European Journal of Cancer, 2015, 51, S209-S210.	1.3	0
157	1863 First line trastuzumab- or lapatinib-based therapy in her2-positive metastatic breast cancer patients after prior (neo)adjuvant trastuzumab. European Journal of Cancer, 2015, 51, S286.	1.3	0
158	PO62 FIRST LINE TRASTUZUMAB-BASED THERAPY IN HER2-POSITIVE METASTATIC BREAST CANCER PATIENTS PRESENTING WITH DE NOVO OR RECURRENT DISEASE: A MULTICENTER RETROSPECTIVE COHORT STUDY. Breast, 2015, 24, S43.	0.9	0
159	First line trastuzumab-based therapy in her2-positive metastatic breast cancer patients presenting with de novo or recurrent disease. Annals of Oncology, 2015, 26, vi10.	0.6	0
160	The OECl Certification/Designation Program: The Genoa Experience. Tumori, 2015, 101, S19-S20.	0.6	0
161	Reply to letter to the editor -Primum non nocere- by Templeton and Åeruga. Annals of Oncology, 2015, 26, 2198-2199.	0.6	0
162	Concurrent versus sequential adjuvant chemo-endocrine therapy in early stage hormone receptor-positive breast cancer patients: a systematic review and meta-analysis. Annals of Oncology, 2016, 27, iv62.	0.6	0

#	ARTICLE	IF	CITATIONS
163	Neoadjuvant therapy with FEC followed by weekly paclitaxel and concurrent trastuzumab in Her2 positive non operable breast cancer: a phase II study. <i>Annals of Oncology</i> , 2016, 27, iv70.	0.6	0
164	TP53 germline mutation testing in early onset breast cancer. <i>Annals of Oncology</i> , 2016, 27, iv71.	0.6	0
165	NAB-Paclitaxel (NAB-P) in HER2-ve Advanced Breast Cancer (ABC) Patients (PTS): Focus on Luminal Cancers. Results from GIM13-AMBRA Study. <i>Breast</i> , 2017, 36, S51-S52.	0.9	0
166	Changes in hormone-receptor status in luminal breast cancers between primary tumour and metastases: Results of the observational cohort GIM-13 AMBRA study. <i>Annals of Oncology</i> , 2019, 30, v113.	0.6	0
167	Application of newer adjuvant treatments for node positive (N+) breast cancer (BC) patients (pts) in Italian centers. Results of the NORA (National Oncological Research Observatory on Adjuvant Therapy) Tj ETQq1 1 0.384314 ogBT /Over	0.384314	0
168	How Italian oncologists cope with end-of-life care: A pilot study. <i>Journal of Clinical Oncology</i> , 2008, 26, 20554-20554.	0.8	0
169	Budget impact analysis of the use of lapatinib in the treatment of breast cancer in Italy. <i>Farmeconomia E Percorsi Terapeutici</i> , 2009, 10, 33-46.	0.2	0
170	Identification of a Prognostic Signature Based on the Expression of Insulin-Related Genes in Early Breast Cancer.. , 2009, , .		0
171	ERCC1, BRCA1, thymidylate synthase (TS), class III beta tubulin (bTubIII), p53R2, RRM2 immunohistochemical expression in stage I-III non-small cell lung cancer (NSCLC): A tissue microarray (TMA) study.. <i>Journal of Clinical Oncology</i> , 2010, 28, e21094-e21094.	0.8	0
172	Pegfilgrastim (P) administration after 24, 72, or 96 hours (h) to allow dose-dense (DD) anthracycline- and taxane-based chemotherapy (CT) in breast cancer (BC) patients (pts): A single-center experience within the GIM2 randomized phase III study.. <i>Journal of Clinical Oncology</i> , 2014, 32, 9632-9632.	0.8	0
173	First line trastuzumab-based therapy in HER2-positive metastatic breast cancer patients (MBC) presenting with de novo or recurrent disease.. <i>Journal of Clinical Oncology</i> , 2015, 33, e11575-e11575.	0.8	0
174	Abstract P5-15-07: First and further line choices of treatment for HER2-VE metastatic breast cancer (MBC) according to adjuvant treatment and biological subtype. Preliminary results of the observational "GIM-13" AMBRA Italian study. , 2017, , .		0
175	First-line therapy with fulvestrant (FUL) in HR+ve, HER2-ve advanced pre-treated breast cancer (ABC) patients (pts): Results from the GIM-13 AMBRA Study.. <i>Journal of Clinical Oncology</i> , 2018, 36, e13032-e13032.	0.8	0
176	Nab-paclitaxel (Nab-P) in patients (pts) with HER2-ve advanced breast cancer (ABC): A focus on the elderly" Preliminary results of the GIM-13 AMBRA study.. <i>Journal of Clinical Oncology</i> , 2018, 36, e13078-e13078.	0.8	0
177	Progression-free survival (PFS) and overall survival (OS) in HER2-ve advanced breast cancer (ABC) patients (pts) according to the molecular subtype in the era of modern agents: Results from the GIM-13 AMBRA study.. <i>Journal of Clinical Oncology</i> , 2019, 37, e12528-e12528.	0.8	0